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OBJECTIVE — Chronic renal insufﬁciency and/or proteinuria in type 2 diabetes may stem
from chronic renal diseases (CKD) other than classic diabetic nephropathy in more than one-
third of patients. We interrogated urine proteomic proﬁles generated by surface-enhanced laser
desorption/ionization-time of ﬂight/mass spectrometry with the aim of isolating a set of biomar-
kers able to reliably identify biopsy-proven diabetic nephropathy and to establish a stringent
correlation with the different patterns of renal injury.
RESEARCH DESIGN AND METHODS — Ten micrograms of urine proteins from 190
subjects(20healthysubjects,20normoalbuminuric,and18microalbuminuricdiabeticpatients
and 132 patients with biopsy-proven nephropathy: 65 diabetic nephropathy, 10 diabetic with
nondiabeticCKD[nd-CKD],and57nondiabeticwithCKD)wererunusingaCM10ProteinChip
arrayandanalyzedbysupervisedlearningmethods(ClassiﬁcationandRegressionTreeanalysis).
RESULTS — The classiﬁcation model correctly identiﬁed 75% of patients with normoalbu-
minuria, 87.5% of those with microalbuminuria, and 87.5% of those with diabetic nephropathy
when applied to a blinded testing set. Most importantly, it was able to reliably differentiate
diabetic nephropathy from nd-CKD in both diabetic and nondiabetic patients. Among the best
predictors of the classiﬁcation model, we identiﬁed and validated two proteins, ubiquitin and
2-microglobulin.
CONCLUSIONS — Our data suggest the presence of a speciﬁc urine proteomic signature
able to reliably identify type 2 diabetic patients with diabetic glomerulosclerosis.
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D
iabetic nephropathy is one of the
most relevant long-term complica-
tions of diabetes in terms of mor-
bidity and mortality and currently
accountsforupto50%ofpatientsrequir-
ingrenalreplacementtherapyinthewest-
ern world, although its prevalence varies
largely among countries (1). By extension
fromtype1diabetes,microalbuminuriais
usually viewed as the earliest putative di-
agnostic sign of diabetic renal damage
also in type 2 diabetes. Indeed, mi-
croalbuminuria grossly correlates with
the complex histopathological picture of
glomerular and tubular damage (2), thus
probably representing a nonspeciﬁc indi-
cator of ongoing renal injury. Moreover,
micro- and macroalbuminuria can stem
from chronic nonspeciﬁc changes related
to vascular damage (arterio-arterioloscle-
rosis and ischemic glomerular lesions) as
well as nondiabetic glomerular diseases,
which may occur either alone or together
with diabetic glomerulosclerosis (3). To
date, an accurate diagnosis of histological
damage in diabetes can only be achieved
by renal biopsy, which points to the need
for easier and noninvasive tools to help
deﬁne kidney damage and, possibly,
drive therapeutic options.
Over the last few years, proteomics, a
novel science focused on analyzing global
proteincontentofabiologicalsample,has
been applied to the search for novel bio-
markers of diabetic and nondiabetic
chronic kidney disease (CKD) (4–7).
Very recently, proteomic-based strategies
to discover urine or serum biomarkers of
diabetic nephropathy have been exten-
sively reviewed (8). Among the available
proteomic approaches, the so-called pro-
ﬁling methods are gaining remarkable
success as promising tools for the identi-
ﬁcation of new putative biomarkers of di-
abetic nephropathy (9–12).
In this study, we implemented super-
vised statistical methods [Classiﬁcation
and Regression Tree (CART) analysis] for
the analysis of urine protein patterns gen-
erated by surface-enhanced laser desorp-
tion/ionization (SELDI)-time of ﬂight
(TOF)/mass spectrometry (MS) to evalu-
ate their ability to distinguish biopsy-
proven diabetic nephropathy from other
forms of CKD in both nondiabetic and
diabetic patients.
RESEARCH DESIGN AND
METHODS— We ﬁrst recruited a
groupof65type2diabeticpatientswitha
steadydeclineinglomerularﬁltrationrate
(GFR) and various degrees of urine albu-
min excretion rate, with biopsy-proven
diabetic nephropathy and without any
histologicalevidenceofconcomitantnon-
diabetic glomerular or vascular disease.
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patients with diabetes and CKD other
than diabetic nephropathy (5 with mem-
branous glomerular nephropathy, 2 with
IgA nephropathy, 2 with focal segmental
glomerular sclerosis, and 1 with athero-
embolic disease). Of note, patients with
diabeticnephropathycamefromthreein-
dependent Divisions of Nephrology: Uni-
versity of Foggia (n  32), Sant’Orsola
Malpighi Hospital, University of Bologna
(n  5), and University of Modena and
Reggio Emilia (n  28). Next, we re-
cruited 38 diabetic patients without any
deterioration of estimated GFR (eGFR),
20 who were normoalbuminuric (NAD
group) and 18 who were microalbumin-
uric(MICROgroup).Finally,weenrolled
57 nondiabetic patients with CKD (nd-
CKD),namelyIgAnephropathy(n20),
membranous nephropathy (n  24) and
benign nephroangiosclerosis (n  13).
Twentyhealthysubjectswererecruitedas
controlgroup.Theclinicalandlaboratory
features of all the subjects studied are re-
ported in supplementary Table A1 (avail-
able in an online appendix at http://
care.diabetesjournals.org/cgi/content/
full/dc10-0345/DC1).
eGFR was calculated using the Modi-
ﬁed Diet in Renal Disease six-variable for-
mula. Most patients examined showed
fair blood pressure and glycemic control
atthetimeofurinecollection.Inaddition,
most of them, with the exception of pa-
tients in NAD group, were taking ACE
inhibitors and/or angiotensin II receptor
antagonistsasapartoftheirantihyperten-
sion treatment.
The study was approved by the local
ethics committee, and informed written
consent was obtained from all participat-
ing subjects. All investigations were con-
ducted according to the principles
expressed in the Declaration of Helsinki.
Renal biopsy examination
Parafﬁn-embedded renal specimens were
used for conventional histological stain-
ing (hematoxylin-eosin, periodic acid-
Schiff, silver methenamine, and Masson’s
trichrome).Immunoﬂuorescencemicros-
copy was performed on cryostat sections
with the use of antisera against IgG, IgM,
IgA, C3, C4, C1q, and ﬁbrinogen. Dia-
betic nephropathy was diagnosed in the
presence of nodular or diffuse glomerulo-
sclerosis, glomerular hypertrophy, mes-
angial (diffuse or nodular) widening,
glomerular capillary wall thickening, evi-
dence of exudative lesions or ﬁbrin caps
(i.e., hyaline material heaped up on the
inner side of the glomerular basement
membrane), and the presence of microa-
neurysms of glomerular capillaries (13).
Patients with concomitant evidence of
nondiabetic glomerular disease or vascu-
lar disease were excluded from the
analysis.
Urine collection and management
Urine samples were collected in the
morning, after overnight fasting, and
tested for standard parameters (including
pH, glucose, blood content, and speciﬁc
gravity) using Multistix reactive stripes
(Bayer Diagnostics, Munich, Germany).
Thentheywerecentrifugedtoremovecell
debris, divided into aliquots with the ad-
ditionofproteaseinhibitors,andstoredat
80°C until analysis.
SELDI proﬁling
Urine samples were concentrated by
3-kDa cutoff Amicon ﬁlter devices (Milli-
pore, Billerica, MA), and 10 g of urine
proteins, diluted (2:3, v/v) with a dena-
turing buffer solution (9 mol/l urea, 2%
3-[(3-cholamidopropyl)dimethylammo-
nio]propanesulfonate [CHAPS], and 100
mmol/l dithiothreitol), were analyzed in
duplicate using a CM10 ProteinChip
(Bio-Rad, Hercules, CA) array, whose
chemical surface binds proteins by cat-
ionicexchange.Allexperimentswereper-
formed according to the manufacturer’s
instructions. At the end of each experi-
ment, the chips were read by a Protein-
Chip Reader (PCS-4000 Enterprise
version; Bio-Rad) and, after acquisition,
the spectra were analyzed by ProteinChip
DataManager 3.5 software (Bio-Rad). Be-
fore each analysis, the software was exter-
nally calibrated by using a protein
standard kit (ProteinChip OQ kit; Bio-
Rad), and all of the spectra were normal-
ized by means of total ion current. The
analysis was performed in a range of
3,000 to 30,000 m/z, considering as real
peaks those having a signal-to-noise and
valley depth ratio 4. The reproducibil-
ity of the SELDI analysis was assessed by
running one urine sample in quadrupli-
cate and measuring the percent coefﬁ-
cient of variation in the number and
intensity of mass peaks. According to our
previously published data (14) and the
manufacturer’s instruction, percent coef-
ﬁcient of variation values for the number
and intensity of peaks were about 8 and
23%, respectively (data not shown).
CART analysis
Urine samples were divided into a train-
ing set and a testing set to construct and
validate the classiﬁcation tree, respec-
tively.Theintensity(microamperes)ofall
the mass peaks in the training set was
transferredtoBiomarkerPatternSoftware
(Bio-Rad) that identiﬁed a set of mass
peaks whose intensity allowed us to clas-
sify each sample of the training set with
the least error. The independent testing
set was then scored using the classiﬁca-
tion tree to evaluate the classiﬁcation
power on a blinded dataset. The sensitiv-
ity was deﬁned as the probability of pre-
dicting diabetic nephropathy, and the
speciﬁcity was deﬁned as the probability
of predicting nd-CKD.
Multivariate analysis
A logistic regression model was used to
determine factors signiﬁcantly related to
the urinary proteomic signature. Signiﬁ-
cance 0.05 for simple logistic analysis
was required for independent variables to
be entered into a multivariate logistic
model.
Protein identiﬁcation and validation
Two proteins of about 11,700 and 8,589
m/z, chosen among the most prominent
predictors included in the classiﬁcation
tree, were isolated, identiﬁed by tandem
mass spectrometry, and validated by en-
zyme-linked immunosorbent assay
(ELISA) (2-microglobulin [2MG]) and
immunoprecipitation(ubiquitin),respec-
tively (for details of methods, see supple-
mentary data, available in an online
appendix).
RESULTS
Differential diagnosis between
diabetic nephropathy and nd-CKD
We ﬁrst tested the ability of Biomarker
Pattern Software to differentiate diabetic
nephropathyfromnd-CKD(Fig.1A).Ini-
tially,urinesamplesfrom54patientswith
diabetic nephropathy and 57 nondiabetic
patients with nd-CKD were distributed
intothetrainingset(31diabeticnephrop-
athy and 41 nd-CKD) and the testing set
(23 diabetic nephropathy and 16 nd-
CKD). To minimize the inﬂuence of pre-
analytical biases on the classiﬁcation
approach, urine samples of patients with
diabetic nephropathy collected in three
distinctnephrologyunitswereevenlydis-
tributed in both the training and the test-
ingset.Thebestclassiﬁcationtreecreated
in the training set was then applied to an
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urine samples to validate its discrimina-
tory power. Diabetic nephropathy and
nd-CKD were correctly classiﬁed with
78.2 and 87.5% sensitivity and speciﬁc-
ity, respectively (Fig. 1B). Eighteen mass
peaks (8,586, 13,593, 13,687, 8,515,
8,665, 11,724, 8,423, 13,902, 13,780,
19,335, 6,320, 13,422, 4,115, 4,049,
Figure 1—Classiﬁcation and regression tree analysis of diabetic nephropathy and nd-CKD. A: Histological picture of one patient with diabetic
nephropathy and one patient with nd-CKD and their respective SELDI urine protein proﬁles. B: Prediction success of CART analysis on the training
set (upper table) and on the testing set with nondiabetic (intermediate table) and diabetic (lower table) patients with nd-CKD. C: ROC analysis of
theabilityoftheproteomicsignaturetoidentifydiabeticnephropathy.DN,biopsy-provendiabeticnephropathy;nd-CKD1,nondiabeticpatientswith
nondiabeticchronickidneydisease;nd-CKD2,diabeticpatientswithnondiabeticchronickidneydisease.(Ahigh-qualitydigitalrepresentationofthis
ﬁgure is available in the online issue.)
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identiﬁed as the best predictors for the
diagnosis of diabetic nephropathy. More-
over, receiver operator characteristic
(ROC) analysis showed 80% accuracy in
the diagnosis of diabetic nephropathy
(Fig. 1C). Next, we were interested in ex-
amining the discriminatory power of the
classiﬁcationtreetowarddiabeticpatients
with CKD other than diabetic nephropa-
thy. To this purpose, the diabetic ne-
phropathy urine signature was scored on
a second independent testing set includ-
ing 11 newly recruited patients with dia-
betic nephropathy and 10 diabetic
patients with nd-CKD. The diabetic ne-
phropathy classiﬁcation tree correctly
distinguished diabetic nephropathy from
nd-CKD with 80% speciﬁcity, as further
conﬁrmed by ROC analysis (Fig. 1B and
C). The accuracy of the proteomic signa-
turetodiscriminatediabeticnephropathy
from nd-CKD was thus largely indepen-
dent from the presence or the absence of
diabetes in patients with nd-CKD.
To further explore the relationship
between proteomic signature and histo-
logical diagnosis, we applied logistic re-
gression analysis, selecting a wide range
of clinical, laboratory, and demographic
variables (age, sex, duration of diabetes,
blood pressure levels, eGFR, daily pro-
teinuria, use of renin-angiotensin system
[RAS] blockers, and smoking) and setting
the proteomic signature as the dependent
nominal variable (absent/present). Sim-
ple logistic analysis showed that only
smokingwassigniﬁcantlyassociatedwith
the diabetic nephropathy signature.
Whensmokingandhistologicaldiagno-
sis were entered into a multiple logistic
model,onlythelatterindependentvari-
able retained the same coefﬁcient, indi-
cating the lack of a signiﬁcant
confounding effect of smoking (not
shown).
Setup of a classiﬁcation tree to
discriminate normoalbuminuria,
microalbuminuria, and biopsy-
proven diabetic nephropathy
WeexaminedtheabilityofCARTanalysis
to discriminate among diabetic patients
with normoalbuminuria, microalbumin-
uria, and diabetic nephropathy. Thirty-
eight patients from all classes (16 with
diabetic nephropathy, 10 with mi-
croalbuminuria, and 12 with normoalbu-
minuria) were used to constitute the
training sample group, whereas the re-
maining 8 samples of each group were
used as a testing set. We chose to limit
the analysis to 24 randomly selected pa-
tientswithdiabeticnephropathyof65pa-
tients because a higher prevalence of
diabetic nephropathy in the training set
and mainly in the testing set could inﬂu-
encetheresultsoftheanalysis.Theinten-
sity of all the protein peaks and the
presence or absence of diabetic retinopa-
thy were used to construct the classiﬁca-
tory model. Among the differently
expressed mass peaks, those of 10,533,
7,919,8,185,9,072,9,135,3,396,8,982,
22,735, 8,847, 22,245, 17,084, and
16,710 m/z were identiﬁed as the best
predictors to set up the discriminatory
tree. The cross-validation of the model on
the training set showed 100% correct
classiﬁcation for all groups. When the
classiﬁcation tree was applied to the
blinded testing set, seven of eight patients
(87.5%) of the MICRO and diabetic ne-
phropathy groups and six of eight pa-
tients (75%) of the NAD group were
correctly classiﬁed (Fig. 2A). The ROC
curve for diabetic nephropathy showed a
diagnostic power of 84% for the current
analysis (Fig. 2B).
Because many variables (sex, dura-
tion of diabetes, blood pressure levels,
eGFR, daily proteinuria, use of RAS
blockers, and smoking) differed among
groups,weexaminedtheirimpactonpro-
teomic proﬁle, set as a dependent polyto-
mous variable, by logistic analysis.
Nonetheless, none of the independent
variables reached a signiﬁcance 0.05 at
simple logistic analysis.
Protein identiﬁcation
We examined and identiﬁed two mass
peaks (11,700 and 8,589 m/z) among
the most prominent predictors included
in the classiﬁcation tree for diabetic
nephropathy.
2MG
The 11,700 m/z peak was identiﬁed as
2-microglobulinbymatrix-assistedlaser
desorption ionization-TOF/tandem mass
spectrometry (supplementary Figure A1,
available in an online appendix). To ex-
ploretherelationshipbetween2MGuri-
Figure 2—CART analysis of diabetic patients with normoalbuminuria, microalbuminuria, and diabetic nephropathy. A: Prediction success of the
CART analysis for the training set (upper table), after 10-fold cross-validation and the independent testing set (lower table). B: ROC analysis of the
ability of the proteomic signature to identify diabetic nephropathy. DN, biopsy-proven diabetic nephropathy; MICRO, microalbuminuric diabetic
patients; NAD, normoalbuminuric diabetic patients.
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we compared 2MG levels in the urine of
diabetic patients with and without dia-
betic nephropathy (Fig. 3A, top panel) by
SELDIproﬁlingandmeasured2MGuri-
nary excretion in patients with diabetic
nephropathy and nd-CKD by ELISA (Fig.
3A,bottompanel).2MGurineexcretion
was considerably higher in diabetic pa-
tients with diabetic nephropathy com-
pared with that for the NAD or MICRO
groups or for patients with nd-CKD.
Ubiquitin
The 8,589 m/z peak was provisionally
identiﬁed as ubiquitin on the basis of its
molecular weight and of the available lit-
eratureonputativebiomarkersofdiabetic
nephropathy. To conﬁrm the identiﬁca-
tion, a recombinant ubiquitin standard
was loaded on a blank spot of the CM10
ProteinChiparray,anditsmassandshape
were compared with those of the 8,589
m/z peak in the protein proﬁles of the pa-
tients (supplementary Figure A2, avail-
able in an online appendix). Further, we
immunoprecipitated ubiquitin from the
urine of six patients with diabetic ne-
phropathy and eight patients with nd-
CKD, and each immunoprecipitate was
then analyzed by a CM10 ProteinChip ar-
ray to conﬁrm the increased excretion of
ubiquitin in urine samples from patients
with diabetic nephropathy (Fig. 3B).
CONCLUSIONS — The data reported
in the present work suggest that the anal-
ysis of urine protein proﬁles of type 2 di-
abetic patients, as generated by SELDI-
TOF/MS with a CM10 ProteinChip, can
be considered a reliable method to iden-
tify patients with diabetic nephropathy
among diabetic patients and, more im-
portantly, to distinguish biopsy-proven
diabetic nephropathy from nd-CKD in
both diabetic and nondiabetic patients.
Currently, microalbuminuria is the
only noninvasive marker of early diabetic
nephropathy. However, microalbumin-
uria may instead reﬂect the existence of
endothelialdamage,intheabsenceofspe-
ciﬁc renal lesions, or, on the contrary, be
associated with advanced renal patholog-
ical changes. Furthermore, clinically
overt nephropathy and/or albuminuria in
diabetic patients does not necessarily im-
ply the presence of diabetic glomerulo-
sclerosis. In the largest histological study
(393 renal biopsies) performed to date,
other glomerulonephritides superim-
posed on diabetic glomerulosclerosis or
glomerulonephritides without the pres-
ence of diabetic nephropathy occurred in
up to 57% of patients (3). Moreover, pa-
tientswithtype2diabetescanprogressto
a signiﬁcant degree of renal impairment
even if they remain normoalbuminuric,
and this occurrence may reﬂect renal pa-
renchymal diseases other than classic di-
abetic glomerulosclerosis (15). Diabetic
patients with nd-CKD have a different
rateofGFRdecline(16,17)and,moreim-
portantly, may be amenable to speciﬁc
treatments. At present, however, there is
not a strong predictor to differentiate di-
abetic nephropathy from nd-CKD by
clinical or biochemical data. Given this
background, novel biomarkers for earlier
diagnosis of diabetes-related renal dam-
age as well as for the proper identiﬁcation
Figure 3—Validation of 2MG and ubiquitin differential excretion. A, top: Representative SELDI spectra (gel view) showing 2MG excretion in
patients with diabetic nephropathy compared with that in healthy subjects and patients with normoalbuminuria, microalbuminuria (left), and
nd-CKD (right). Bottom: 2-MG urine (U) excretion as measured by ELISA (mean  SEM) in patients with diabetic nephropathy compared with
nd-CKD. B, top: Ubiquitin urine excretion as measured by SELDI analysis on the whole urine proﬁle (mean  SEM) in patients with diabetic
nephropathy compared with nd-CKD. Bottom: SELDI proﬁling of urine ubiquitin immunoprecipitated by a speciﬁc monoclonal antibody (ubiquitin
IP) and run on a CM10 ProteinChip array. Representative SELDI spectra (gel view) from six patients with diabetic nephropathy and eight patients
with nd-CKD are shown. *P  0.05. DN, biopsy-proven diabetic nephropathy; MICRO, microalbuminuric diabetic patients; HS, healthy subjects;
NAD, normoalbuminuric diabetic patients.
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cially required.
Over the last several years, only a few
studieshaveadoptedproteomicstrategies
focused on identifying one or more urine
biomarkers that would allow either the
earlydetectionofdiabeticnephropathyor
its discrimination from other nd-CKD or
the identiﬁcation of normoalbuminuric
type 2 diabetic patients prone to develop
diabetic nephropathy (10–12,18,19). All
of them, however, identiﬁed diabetic ne-
phropathy exclusively on a clinical basis
(i.e., the presence of macroalbuminuria
withorwithoutadeclineofeGFR),which
may potentially lead to a misclassiﬁcation
in more than one-third of patients in the
absence of histological veriﬁcation (3).
Moreover,moststudiesfailedtoapplysu-
pervised learning algorithms to validate
the proposed signatures.
The main aim of the present study
was to identify biopsy-proven diabetic
nephropathy by urine proteomic ﬁnger-
print. We therefore started by comparing
the urine proteome of 54 biopsy-proven
diabeticnephropathywiththatof57non-
diabetic patients with proteinuria and
CKD. CART analysis of the blinded test-
ing set revealed 78.2 and 87.5% sensitiv-
ity and speciﬁcity, respectively, thus
indicating that the urine proteome con-
tains a set of key information useful to
accuratelydistinguishbiopsy-provendia-
betic nephropathy from nd-CKD. More-
over, multivariate analysis allowed us to
rule out the confounding effect of a num-
ber of potentially relevant covariates (see
RESULTS). To corroborate the discrimina-
tory power of the classiﬁcation tree, we
tested the urinary ﬁngerprint of biopsy-
proven diabetic nephropathy in a further
group of 21 diabetic patients, 11 with di-
abeticnephropathyand10withnd-CKD.
CART analysis identiﬁed patients with di-
abetic nephropathy with 80% accuracy,
thusdemonstratingtheabilityoftheurine
proteomic ﬁngerprint to discriminate di-
abetic nephropathy from nd-CKD, both
in the presence and in the absence of di-
abetes. However, we are aware that the
small size of the dataset we explored lim-
its the possibility of drawing any ﬁnal
conclusions.
We then applied SELDI protein pro-
ﬁlingtothestudyoftheurineproteomeof
the whole population of diabetic patients
andanalyzedurineproﬁlesbybothunsu-
pervised and supervised learning meth-
ods. When SELDI spectra were analyzed
by unsupervised methods, a list of mass
peaks showed a signiﬁcantly different ex-
pressionamonggroups(datanotshown),
but none of these putative biomarkers
was, by itself, sensitive and speciﬁc
enough to allow a reliable discrimination
among classes. To overcome the limita-
tions of the univariate analysis, we ana-
lyzed SELDI spectra by supervised
learning methods, which screened all
mass peaks to build up an optimal classi-
ﬁcation tree. The classiﬁcation tree cor-
rectly identiﬁed 87.5% of patients with
microalbuminuria and biopsy-proven di-
abetic nephropathy and 75% of patients
with normoalbuminuria in the blinded
test set. The inclusion of a retinopathy
score (present/absent) in the analysis did
not improve the accuracy of the classiﬁ-
cation model (data not shown). Finally,
by logistic analysis we ruled out the pos-
sibility that the urinary proteomic signa-
ture would be signiﬁcantly inﬂuenced by
a number of variables (sex, blood pres-
sure levels, degree of deterioration of
renal function, smoking, and RAS
blocker therapy) differently distributed
among groups.
We must recognize that albuminuria
per se could not properly reﬂect the type
and the degree of renal damage, and this
fact might help explain some apparent
misclassiﬁcation within the groups lack-
ing histological examination. If so, pro-
teomic “signature” might unmask the
existenceofaclinicallysilentrenalinjury.
Indeed, all patients with normoalbumin-
uria were checked again after a median of
1.8 years, but none of them had pro-
gressedtowardmicroalbuminurianordid
they show a deterioration in eGFR. For
thesereasons,wewereunabletocorrelate
the initial misclassiﬁcation of the two
patients with normoalbuminuria with the
progressionofrenaldisease.Wemayinfer
that a longer follow-up is required to as-
certain whether some of the protein
peaks in the normoalbuminuria signa-
ture depicted here would serve as early
predictive biomarkers of diabetic glo-
merulosclerosis in normoalbuminuric di-
abetes (11). Interestingly, all biopsy-
proven diabetic nephropathy showed a
conserved proteomic pattern, indepen-
dent from the individual rate of urine al-
bumin excretion, which supports the
assumption that the albumin excretion
rate does not necessarily reﬂect the type
and degree of renal damage.
The identiﬁcation of some of the
proteins in the proteomic signature of
diabetic nephropathy might provide in-
sight into the mechanisms underlying
thedisease,besidesservingascandidate
biomarkers to diagnose diabetic ne-
phropathy. Therefore, two proteins
8,589 and 11,700 m/z, chosen among
themostprominentpredictorsincluded
in the classiﬁcation tree, were isolated
and identiﬁed as ubiquitin and 2MG,
respectively. Their increased excretion
in the urine of patients with diabetic
nephropathy compared with that in di-
abetic patients without diabetic ne-
phropathy and with nd-CKD was
conﬁrmed by immunoprecipitation
(ubiquitin) or ELISA (2MG) and was
found to be independent of the severity
of daily proteinuria.
Ourﬁndingsareconsistent,atleastin
part, with those reported by Dihazi et al.
(12). These authors found a signiﬁcant
excretionof2MGinproteinuricdiabetic
patients and a selective excretion of ubiq-
uitin ribosomal fusion protein in micro-
and macroalbuminuric diabetic patients,
whoinsteadreleasedverylowamountsof
the truncated form of ubiquitin. These
partial discrepancies may be ascribed to
theuseofproteaseinhibitorsinourstudy,
which possibly prevented ubiquitin-
speciﬁc degradation (12). Regardless, de-
ranged excretion of ubiquitin is a novel
and potentially interesting biomarker of
diabetic nephropathy. At variance, in-
creased levels of urine 2MG, a recog-
nized marker of renal tubular damage,
have long been described in diabetic pa-
tients with micro- and macrovascular
complications and mainly in those with
associatedhypertension(20),aswellasin
diabetic patients with micro- or mac-
roalbuminuria (12), but studies compar-
ing 2MG release in patients with
diabetic nephropathy versus those with
nd-CKD are currently lacking.
In summary, we report that the stan-
dardization of urine analysis by SELDI-
TOF/MS(14,21)andtheelaborationofits
complex datasets by means of supervised
statistical methods allowed us to generate
a robust multiparametric panel of mass
peaks that was able to reliably discrimi-
nate biopsy-proven diabetic nephropathy
from nd-CKD in both diabetic and non-
diabetic patients. These ﬁndings, if con-
ﬁrmed in larger cohorts of diabetic
patients, encourage the use of supervised
learning approaches for the analysis of
urineproteomicproﬁlestoachieveanon-
invasive differential diagnosis of renal le-
sions in diabetic patients, whereas the
appraisal of their possible predictive
power demands longitudinal studies. Fi-
nally, the selective release of high
amounts of ubiquitin and 2MG in the
Diagnosis of diabetic nephropathy by proteomics
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thy may suggest a role as candidate bio-
markers and possible involvement in the
pathophysiology of the disease.
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